Moderna, vaccines, transfection method, luciferase, mRNA, quantum dots, DNA

Moderna Tx COVID Vaccine

Moderna’s Work on a COVID-19 Vaccine Candidate

COVID Vaccine: mRNA-1273

Moderna’s standard Informed Consent Form and Authorization To Use and Disclose Protected Health Information for Protocol # mRNA-1273-P301

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen Preparedness

Transfection Method: Luciferase Spiked Protein

Pseudotyped Luciferase rSARS-CoV-2 Spike for pseudovirus Luciferase Assay (PVLA)

Production of Pseudotyped Particles to Study Highly Pathogenic Coronaviruses in a Biosafety Level 2 Setting

mRNA-1273 SARS-CoV-2 Vaccine

mRNA-1273 is an mRNA vaccine candidate against the novel coronavirus SARS-CoV-2 encoding for a Prefusion stabilized form of the Spike Protein (Luciferase), which was selected by Moderna in collaboration with investigators at the NIAID Vaccine Research Center.

LIPS method for the detection of SARS‐CoV‐2 antibodies to spike and nucleocapsid proteins

mRna-1273 Vaccine & Quantum Dots

Nanotechnology for COVID-19: Therapeutics and Vaccine Research

Quantum Dots as Strain- and Metabolism-Specific Microbiological Labels

Design of Quantum Dot-Conjugated Lipids for Long-Term, High-Speed Tracking Experiments on Cell Surfaces

One Step Preparation of Quantum Dot-embedded Lipid Nanovesicles by a Microfluidic Device

Modified RNA has a direct effect on DNA

Backup including external links: